Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Rare Variants Associated with Blood Pressure Regulation

By LabMedica International staff writers
Posted on 07 Dec 2020
Genes likely play some role in high blood pressure, heart disease, and other related conditions. More...
However, it is also likely that people with a family history of high blood pressure share common environmental and other potential factors that increase their risk.

High blood pressure, or hypertension, is a common disease in which blood flows through blood vessels at higher than normal pressures. A high force of blood flow can damage and weaken the blood vessels. Over time, hypertension can harm different organs, including the heart, kidneys, brain, and eyes.

A team of scientists at the University of Cambridge (Cambridge, UK) and their colleagues used exome and genotyping arrays for up to 1.3 million individuals of European, African American, South Asian, or Hispanic ancestry enrolled in the large projects such as UK Biobank (UKBB) or in dozens of smaller studies. The team searched for rare variants involved in four main blood pressure-related traits: hypertension, inverse-normal transformed systolic blood pressure, diastolic blood pressure, or pulse pressure. The team relied on exome array-wide association (EAWAS) and rare variant-focused genome-wide association (RV-GWAS) studies and meta-analyses, along with fine-mapping and gene-based analyses, to search for rare variants linked to the blood pressure traits in question.

The investigators found 106 previously undetected loci linked to blood pressure, and dozens of blood pressure-related rare variants, while highlighting enhanced effects for individual rare variants compared to the 1,000 or more common, small effect variants implicated in blood pressure in the past. Just two new loci, in or around the RP11 or VTN genes, had genome-wide significant ties to all of the blood pressure traits considered. Average effects of rare variants were around eight times larger than common variant effects and indicate potential candidate causal genes at new and known loci (for example, GATA5 and PLCB3).

Along with rare variants falling at genes or loci already known to contribute to blood pressure regulation, the team's analysis of common and rare blood pressure-related variants from the new analysis and from studies done before led to active chromatin regions involved in the fetal development of blood vessels, heart, muscle, and other tissues or organs. It also saw genes with potential ties to congenital heart defects, as well as genes with enhanced gene expression during heart development.

Joanna M. M. Howson, PhD, a cardiovascular epidemiologist and a corresponding author of the study, said, “The results from our study indicate rare blood pressure associated variants contribute to blood pressure variability in the general population, and their identification has provided information on new candidate genes and potential causal pathways.” The study was published on November 23, 2020 in the journal Nature Genetics.

Related Links:
University of Cambridge


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Ebola remains a rapidly evolving public health threat with high mortality, underscoring the need for timely diagnosis and decentralized testing closer to patients (Image Credit: Adobe Stock)

Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories

Co-Diagnostics, Inc. (Salt Lake City, UT, USA) and ReadyGo Diagnostics Ltd. (Bath, UK) have initiated a collaboration to evaluate ReadyGo’s GoCollect with the Co-Dx PCR platform for blood-based molecular... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Galleri is designed to detect cancer-specific methylation patterns across multiple cancer types before symptoms appear, including cancers without recommended screening (Photo courtesy of GRAIL)

Multi-Cancer Early Detection Test Wins FDA Panel Backing for Approval

GRAIL’s Galleri multi-cancer early detection (MCED) test was reviewed by the Molecular and Clinical Genetics Devices Panel of the U.S. Food and Drug Administration’s (FDA) Medical Devices Advisory Committee.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.